法尔内西尔转移酶抑制剂作为针对KRAS依赖癌症的新策略
1Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
ACS medicinal chemistry letters
|April 16, 2025
概括
将法纳西转移酶抑制剂 (FTIs) 与KRAS抑制剂结合使用可以克服癌症的适应性抵抗. 这种方法显示了增强瘤抑制和延迟治疗耐药性的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 克拉斯突变是许多癌症的关键驱动因素.
- 直接的KRAS抑制剂面临着适应性耐药性的挑战,限制了临床疗效.
- 补偿信号通路,包括mTOR和MAPK,有助于抵抗.
研究的目的:
- 研究法纳西转移酶抑制剂 (FTIs) 在克服对KRAS抑制剂的适应性耐药性的潜力.
- 评估FTIs和KRAS抑制剂在临床前癌症模型中的联合疗效.
- 探索 FTIs 对补偿路径激活的影响.
主要方法:
- 使用具有KRAS突变的癌症模型的临床前研究.
- 单独使用法内西尔转移酶抑制剂 (FTIs),并与KRAS抑制剂结合使用.
- 信号通路激活 (mTOR,MAPK) 和瘤生长的分析.
主要成果:
- 法内西尔转移酶抑制剂 (FTIs) 显示了补偿mTOR和MAPK通路激活的减少.
- 与单一治疗相比,FTIs和KRAS抑制剂的联合治疗显示出增强的瘤抑制.
- 综合方法表明,有可能延迟适应性耐药性的出现.
结论:
- 法内西尔转移酶抑制剂 (FTIs) 是一种可行的策略,可以增强KRAS抑制剂的作用.
- 组合疗法有望改善KRAS突变癌症的治疗结果.
- 通过FTIs针对补偿途径,可以克服适应性阻力并改善持久反应.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
The Ras Gene
6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.1K


